Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod

Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod

DNA

Published

The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.

Full Article